Back to search results

GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Advanced Solid Tumor · Metastatic Solid Tumor · Cervical Cancer · Urothelial Carcinoma · Clear Cell Renal Cell Cancer (ccRCC) · Squamous Cell Non Small Cell Lung Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Tisch Cancer Institute (TCI), Icahn School of Medicine, New York, New York, United States

    Contact: Principal Investigator (Thomas Marron, MD, PhD)

  • Carolina Biooncology Institute, Huntersville, North Carolina, United States

    Contact: Principal Investigator (John Powderly, M.D., Ph.D.)

  • The Catholic University of Korea Seoul ST.MARY'S Hospital, Seoul, Banpo-daero, South Korea

    Contact: Principal Investigator (In Ho Kim)

  • Seoul National University Bundang Hospital, Seoul, Bundang-gu, South Korea

    Contact: Principal Investigator (EunHee Jung)

  • Chungnam National University Hospital, Daejeon, Daejeon, South Korea

    Contact: Principal Investigator (HyoJin Lee, M.D., Ph.D.)

  • Samsung Medical Center, Seoul, Gangnam, South Korea

    Contact: Principal Investigator (Se Hoon Park)

  • The Catholic University of Korea St. Vincent's Hospital, Suwon, Kyeonggi-do, South Korea

    Contact: Principal Investigator (Byoung-Yong Shim, M.D., Ph.D.)

  • Korea University Anam Hospital, Seoul, Seongbuk-gu, South Korea

    Contact: Principal Investigator (SooHyeon Lee, M.D.)

  • Ewha Womans University Mokdong Hospital, Seoul, Yangcheon-gu, South Korea

    Contact: Principal Investigator (Jeong Min Cho)

  • Yonsei University Health System, Severance Hospital, Seoul, South Korea

    Contact: Principal Investigator (Byoung Chul Cho, M.D., Ph.D.)
    Sang Joon Shin, M.D., Ph.D. (Sub-investigator)

  • Yonsei University Health System, Severance Hospital, Seoul, South Korea

    Contact: Principal Investigator (Jung-Yun Lee, M.D., Ph.D.)

  • Asan Medical Center, Seoul, South Korea

    Contact: Principal Investigator (Jae Lyun Lee, M.D., Ph.D.)
Study leads

  • Nari Yun, PhD

    Study Director

    GI Innovation

View source on ClinicalTrials.gov(opens in a new tab)